(HealthDay)—The U.S. Food and Drug Administration has approved the orphan drug Juxtapid (lomitapide) for patients with homozygous familial hypercholesterolemia (HoFH), for use in combination with a low-fat diet and other ...
Dec 27, 2012
0
0
Acetaminophen, a widely available over-the-counter medication, can cause liver toxicity in children if doses are exceeded, and more public education is needed to warn of potential adverse effects, states an article published ...
Jun 4, 2012
0
0
Using fractionated doses of the targeted anticancer drug gemtuzumab ozogamicin allows for safer delivery of the drug into patients aged 50-70 years with acute myeloid leukaemia (AML) and substantially improves their outcomes. ...
Apr 4, 2012
0
0
(AP) -- A panel of cancer experts overwhelmingly backed the approval of a GlaxoSmithKline drug for a rare type of tumor, noting there are few other treatment options for patients.
Mar 20, 2012
0
0
(Medical Xpress) -- A tiny 3-D collagen "scaffold" developed in a Cornell lab could prove a lifesaver for those who have lost parts of their intestine.
Dec 9, 2011
0
0
New research from the Keck School of Medicine of the University of Southern California (USC) may help prevent damage to the liver caused by drugs like acetaminophen and other stressors.
Sep 7, 2011
0
0
(Medical Xpress) -- Few treatments exist for patients with advanced primary liver cancer, but University of Florida researchers have found a new way to broaden the range of options and potentially improve health outcomes ...
Jul 6, 2011
0
0
Although some people believe that taking selenium can reduce a person's risk of cancer, a Cochrane Systematic Review of randomised controlled clinical trials found no protective effect against non-melanoma skin cancer or ...
May 11, 2011
0
0
It is estimated that about one in four adults worldwide has a liver condition that is a risk factor for heart disease, according to a new American Heart Association scientific statement published today in the Association's ...
Apr 14, 2022
0
53
Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and post-market drug withdrawals. Drug-induced mitochondrial toxicity has been shown to play an essential role in various forms of DILI, ...
Sep 3, 2021
0
2
